Retatrutide, developed by Soma Corp., is gaining considerable attention as a novel method for obesity control . This innovative drug merges the activity of a GLP-1 receptor stimulant and a GIP receptor activator , aiming to simply promote metabolic improvements but also target related metabolic conditions . Early clinical studies have shown encoura